Sprout Health review

Sprout Health facilitates access to compounded semaglutide, tirzepatide and NAD+ with clinician review and pharmacy fulfillment. Product pages describe medication, care access, shipping and supplies as included in the selected offer. Those services can be compared without assuming a preparation has the clinical evidence of an approved brand or that NAD+ improves energy or sleep. The terms identify MD Integrations as a clinical network and name external pharmacy contacts. They do not guarantee that an online prequalification result becomes a prescription. The clinician still decides whether treatment is appropriate after the relevant medical review.

Billing is the material unresolved issue. GLP-1 marketing uses four-week prices, and the current NAD+ page explicitly describes renewal every four weeks after the introductory period. However, the refund policy describes automatic monthly charging, while the how-it-works page’s legacy instructions specify the same calendar date each month. These are different charge schedules, and the latter page now distinguishes legacy portals from the current patient account. Comparison figures are withheld until the selected agreement resolves which schedule actually applies. A four-week interval should not be called calendar monthly, and an annualized cost comparison should not be mistaken for an actual count of cash payments.

The current NAD+ offer includes a vial, home-administration supplies and care access, with separate introductory and recurring terms. Its page also makes broad claims about bioavailability, energy, focus and recovery. Those promotional statements are not evidence that the particular subcutaneous preparation delivers a reliable clinical benefit. Likewise, testimonials and satisfaction figures should not be treated as controlled treatment outcomes. Ask the clinician about the actual formulation, expected monitoring and reasons it may or may not be appropriate. The general molecular role of NAD+ in metabolism does not establish what happens after a patient takes a commercial preparation.

Care instructions also differ by account and clinical need. The current how-it-works page explicitly labels much of its detailed walkthrough as a legacy process and directs patients to the account identified in their order email. That legacy description places purchase before a detailed questionnaire and requires further clinical approval before refills ship. The terms describe synchronous visits for listed states, but that is the company’s service description rather than a current legal determination that everyone elsewhere can skip a live visit. Confirm your actual assessment, refill requirements and processing estimate with the assigned clinician. A stated shipping service begins after medical approval and pharmacy preparation.

The refund policy provides a meaningful order-stage distinction. Cancellation before the prescription is sent to the pharmacy qualifies for a full refund, including after medical review; transmission to the pharmacy generally makes that order nonrefundable. Stopping the next renewal requires notice at least forty-eight hours before the scheduled billing date. A shipment delay or pause needs at least five business days before the scheduled shipment, which is a different deadline. For prepaid plans, the policy describes refunding unshipped months using the actual discounted checkout total divided by the purchased months. It does not support a blanket claim that every unused prepaid balance is nonrefundable.

Delivery concerns require prompt reporting. The policy uses a twenty-four-hour notification for condition or temperature problems but also contains different forty-eight- and seventy-two-hour references, so do not wait for the longest number when a problem appears. Its broad warm-shipping assurances should not override FDA advice about injectable GLP-1 medicines arriving warm or inadequately refrigerated: contact the pharmacist and do not assume the preparation is usable. The FDA warning letter addresses misleading claims that compounded GLP-1s were FDA-approved; it does not establish closure or a defect in every order. Confirm the actual dispensing facility, shipment status and applicable refund or replacement process.